Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

Дата публикации: 28-07-2026 00:00:00

This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	SGLT2 Inhibitors for Prevention of AKI	0	16.3	30-07-2026
2	Spectrum of Aldosteronism and Cardiovascular Outcomes	0	6.27	01-04-2026
3	Efficacy and Safety of Brolucizumab for Diabetic Macular Edema	0	7.97	01-12-2023
4	Cardiovascular Risk Reclassification With the 2026 Dyslipidemia Guideline	0	11.38	18-08-2026
5	Cognitive Outcomes After Catheter Ablation for Atrial Fibrillation	0	8.06	31-07-2026
6	Novo Nordisk Provides Update on the ZEUS Phase 3 Trial of Ziltivekimab in People with ASCVD, CKD and Inflammation	0	12.26	31-07-2026
7	Reticular Pseudodrusen and Cardiovascular Disease or Related Mortality in AREDS and AREDS2	0	8.07	01-07-2026
8	STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study	0	7.41	31-07-2026
9	Kidney cancer drug could slash the risk of repeated heart attacks in a similar way to statins, study suggests	0	8.9	01-09-2024
10	Study questions the value of intensive cardiac surveillance in cancer patients treated with anthracyclines	0	6.46	29-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.74. Источник: archderm.jamanetwork.com.